Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 59 | 1 | 52 | −6 |
| Shares | 60.8M | 5 | 55.7M | −5.10M (−8.4%) |
| Value | $19.5M | $2 | $19.7M | +$238.1K (+1.2%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 15 | $5 | 0.00% |
Sold out (7)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Ergoteles LLC | 102,756 | $33.0K |
| Goldman Sachs Group Inc | 61,548 | $19.8K |
| Tri Locum Partners LP | 38,847 | $12.0K |
| Creative Planning | 18,609 | $5.97K |
| Federated Hermes, Inc. | 3,574 | $1.15K |
| Simplex Trading, LLC | 29 | $0 |
| IFP Advisors, Inc | 29,501 | – |
Not filed for Q1 2023 yet (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| CoreCap Advisors, LLC | 5 | $2 |